Zydus inks licensing agreement with Daewoong Pharmaceutical for leuprolide injectable in the US
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Subscribe To Our Newsletter & Stay Updated